Iloprost

Iloprost, the active ingredient in Iloprost, is a prostacyclin (prostanoid) analog presented as a solution for infusion for intravenous use. It treats pulmonary arterial hypertension and related vascular conditions in adults.

GNH USA supplies Iloprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iloprost acts on the prostacyclin pathway to provide vasodilation in several vascular disorders. - Pulmonary arterial hypertension: improves exercise capacity and hemodynamics by dilating pulmonary arteries. - Digital ulcers associated with systemic sclerosis: promotes ulcer healing through enhanced blood flow and inhibition of platelet aggregation. - Severe peripheral arterial disease (off‑label): may improve limb perfusion and reduce ischemic pain.

Iloprost may cause a range of adverse reactions, most of which are related to its vasodilatory properties.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Nausea: occasional upset stomach. - Diarrhea: loose stools during infusion. - Jaw pain: discomfort in the mandibular area. - Hypotension: drop in blood pressure during administration.

Serious or Rare Side Effects: - Pulmonary edema: accumulation of fluid in the lungs. - Severe bleeding: due to platelet inhibition. - Thrombocytopenia: marked reduction in platelet count. - Acute renal failure: sudden loss of kidney function.

Iloprost requires careful monitoring because of its potent vascular effects. - Cardiovascular monitoring: observe blood pressure and heart rate during infusion. - Bleeding risk: assess for active bleeding or anticoagulant therapy. - Renal function: evaluate kidney function before and during treatment. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Storage: Store at controlled room temperature (below 25°C): keep in original container, protect from light and moisture.

Iloprost can interact with other agents that affect vascular tone or coagulation.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): additive vasodilatory effect may cause severe hypotension. - Anticoagulants (e.g., warfarin, heparin): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may enhance vasodilation. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can affect renal perfusion. - Beta‑blockers: may blunt compensatory heart rate response. - Diuretics: monitor electrolytes and blood pressure.